CD8A and cancer: These results clearly indicated that CTLA4‐checkpoint therapy exerted its anticancer action selectively in CIRT+HCQ isograft‐bearing mice but not in control isograft‐bearing mice, presumably by activating and expanding cancer‐specific CD8+ T cells.